Evaluation of the Serum Levels of IL-1 in Type 2 Diabetic Patients with and without Diabetic Nephropathy
暂无分享,去创建一个
Nahid Niknami | Melody Omraninava | Nazanin Mirzaei | Nazanin Mirzaei | Nahid Niknami | Melody Omraninava
[1] H. Joller-jemelka,et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.
[2] H. Parving,et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study , 2004, BMJ : British Medical Journal.
[3] F. Locatelli,et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] S. Shoelson,et al. Type 2 diabetes as an inflammatory disease , 2011, Nature Reviews Immunology.
[5] R. Foley,et al. End-stage renal disease in the United States: an update from the United States Renal Data System. , 2007, Journal of the American Society of Nephrology : JASN.
[6] J. Nerup,et al. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. , 1986, Science.
[7] G. Hotamisligil,et al. Inflammation and metabolic disorders , 2006, Nature.
[8] M. Donath,et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. , 2001, Diabetes.
[9] A. Whitehead,et al. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.
[10] D. Wesson,et al. Primary hypertension and nephropathy. , 2006, Current opinion in nephrology and hypertension.
[11] G. Jerums,et al. 3: Preventing complications of diabetes , 2003, The Medical journal of Australia.
[12] T. Mandrup-Poulsen,et al. The role of interleukin-1 in the pathogenesis of IDDM , 1996, Diabetologia.
[13] Allan Vaag,et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.
[14] J. Navarro-González,et al. The role of inflammatory cytokines in diabetic nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.
[15] Richard A. Flavell,et al. Inflammasomes in health and disease , 2012, Nature.
[16] J. Pickup. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. , 2004, Diabetes care.
[17] G. Rossi,et al. Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.
[18] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[19] J. Sturis,et al. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. , 2004, Diabetes.
[20] M. Crook. Type 2 diabetes mellitus: a disease of the innate immune system? An update , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[21] Rury R Holman,et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.